Reuters logo
BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran
November 7, 2017 / 12:18 PM / in a month

BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran

Nov 7 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam initiates ENVISION Phase 3 clinical study with givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias (AHPs)

* Alnylam Pharmaceuticals Inc - ‍intends to file a new drug application (NDA) for givosiran at or around year-end 2018​

* Alnylam Pharmaceuticals Inc - ‍also reached alignment on ENVISION Phase 3 study design with European Medicines Agency​

* Alnylam Pharmaceuticals - reiterating previous guidance that it expects to report interim analysis data in mid-2018 from ENVISION Phase 3​ study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below